USAID Medicines, Technologies, and Pharmaceutical Services Program, Management Sciences for Health, Inc, Arlington, Virginia, USA
Program Delivery Group, Management Sciences for Health, Inc, Arlington, Virginia, USA.
BMJ Glob Health. 2020 Aug;5(8). doi: 10.1136/bmjgh-2020-003181.
Many low-income and middle-income countries lack the capacity to effectively and efficiently regulate medical products in their countries. To support countries in strengthening their capacity, WHO has developed the Global Benchmarking Tool (GBT) as the global standard for objectively assessing regulatory capacity for medicines and vaccines. The GBT is a game changer because it is the first globally accepted tool for assessing and strengthening national regulatory authorities. The inclusion of an institutional development plan in the GBT methodology provides context-specific actionable steps countries can take to advance their system's functionality and maturity. The GBT facilitates coordination and improves the effectiveness of regulatory strengthening efforts. The tool also facilitates regulatory reliance and harmonisation, which helps to improve timely access to quality-assured medicines, and creates incentives for trade, particularly in countries and regions with a strong pharmaceutical manufacturing base. The GBT is a necessary tool for creating strong and effective regulatory systems, which are critical for ensuring the efficacy, safety and quality assurance of medicines and populations' timely access to these medicines. In outlining the benefits of the GBT, this paper also offers some specific ideas for strengthening the GBT framework and process.
许多低收入和中等收入国家缺乏在本国有效和高效监管医疗产品的能力。为支持各国加强能力,世卫组织开发了全球基准工具(GBT),将其作为客观评估药品和疫苗监管能力的全球标准。GBT 是一个具有变革意义的工具,因为它是第一个被全球认可的评估和加强国家监管机构的工具。GBT 方法中纳入体制发展计划,为各国提供了可采取的具体行动步骤,以推进其系统的功能和成熟度。GBT 促进协调并提高监管加强工作的成效。该工具还促进监管依赖和协调,有助于改善及时获得质量有保证的药物的机会,并为贸易创造激励,特别是在具有强大制药制造基础的国家和区域。GBT 是建立强大和有效的监管系统的必要工具,这对于确保药物的疗效、安全性和质量保证以及民众及时获得这些药物至关重要。本文在概述 GBT 的益处时,还提出了一些具体的想法,以加强 GBT 框架和流程。